BMC Cancer 2008, 8:19 http://www.biomedcentral.com/1471-2407/8/19 Additional file 2 Complete lists of the genes identified in the RGP and Met libraries. The tables contain the identifier and annotation of the genes represented in the RGP and Met libraries and indicate the number of occurrences for each gene among the clones sequenced from each library. Click here for file [http://www.biomedcentral.com/content/supplementary/1471- 2407-8-19-S2.pdf] Additional file 3 Schematic representations of the sequence alignments of ESTs from the RGP and Met libraries that match intronic or intergenic regions. The data indicate that some of the sequences identified in the subtractive libraries may correspond to novel transcripts. Click here for file [http://www.biomedcentral.com/content/supplementary/1471- 2407-8-19-S3.pdf] Additional file 4 Lists of the genes represented by redundant clones in the RGP and Met libraries. The tables contain the identifier, Gene Ontology annotation and available information about role in cancer related processes for the genes represented by redundant clones in the RGP and Met libraries. Click here for file [http://www.biomedcentral.com/content/supplementary/1471- 2407-8-19-S4.pdf] Additional file 5 Search for the expression profile of the genes identified in the RGP and Met libraries in a melanoma microarray study performed by Hoek et al. [92]. Lists of the genes represented in the RGP and Met libraries that were detected as differentially expressed between melanocytes and melanoma cell lines in the above cited study. Click here for file [http://www.biomedcentral.com/content/supplementary/1471- 2407-8-19-S5.pdf] Additional file 6 Search for the expression profile of the genes identified in the RGP and Met libraries in the proteomics and SAGE analyses performed by de Souza et al. [93]. Lists of the genes represented in the RGP and Met libraries that were detected as differentially expressed between non-tumorigenic and tumorigenic murine melanocytic cell lines in the above cited study. Click here for file [http://www.biomedcentral.com/content/supplementary/1471- 2407-8-19-S6.pdf] Acknowledgements We are especially grateful to Dr Meenhard Herlyn (Wistar Institute, Phila- delphia, PE, USA) for the collection of human melanoma cell lines that he kindly provided to us. We are thankful to Michel Mozinho dos Santos e Raul Torrieri for assistance with the bioinformatics analysis; Silmara Reis Banzi, Benedita Oliveira Souza and Sarah Cristina Freitas de Mello for technical assistance, as well as to Dr Marcelo Brocchi (former professor at our department, now at UNICAMP) and Dr Marco Antonio Zago (Hemocen- tro de Ribeirão Preto/SP) for making sequencing machines available to our project. We thank FAPESP, CNPq and FAEPA for research support to our laboratory and CNPq for a post-doctorate fellowship to J.F.S. during 2006 and a current research fellowship to E.M.E. Also, we thank FAPESP for a current post-doctorate fellowship to J.F.S. References 1. Grossman D, Altieri DC: Drug resistance in melanoma: mech- anisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001, 20(1-2):3-11. 2. Helmbach H, Rossmann E, Kern MA, Schadendorf D: Drug-resist- ance in human melanoma. Int J Cancer 2001, 93(5):617-622. 3. Soengas MS, Lowe SW: Apoptosis and melanoma chemoresist- ance. Oncogene 2003, 22(20):3138-3151. 4. Meier F, Satyamoorthy K, Nesbit M, Hsu MY, Schittek B, Garbe C, Herlyn M: Molecular events in melanoma development and progression. Front Biosci 1998, 3:D1005-10. 5. Kath R, Jambrosic JA, Holland L, Rodeck U, Herlyn M: Development of invasive and growth factor-independent cell variants from primary human melanomas. Cancer Res 1991, 51(8):2205-2211. 6. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P, Clark WH, et al.: Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985, 45(11 Pt 2):5670-5676. 7. Hsu MY Elder, D. E., Herlyn, M.: Melanoma: The Wistar Melanoma (WM) Cell Lines. In Human Cell Cultures Volume 1. Kluwer Academic Publishers; 1999:259-274. 8. Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M: Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998, 153(5):1435-1442. 9. Herlyn M, Balaban G, Bennicelli J, Guerry D, Halaban R, Herlyn D, Elder DE, Maul GG, Steplewski Z, Nowell PC, et al.: Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 1985, 74(2):283-289. 10. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M: Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/ phosphatidylinositol 3-kinase-Akt pathways and up-regulat- ing N-cadherin expression. Cancer Res 2006, 66(8):4182-4190. 11. Ryu B, Kim DS, Deluca AM, Alani RM: Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE 2007, 2(7):e594. 12. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast can- cer. Nature 2002, 415(6871):530-536. 13. Bernards R, Weinberg RA: A progression puzzle. Nature 2002, 418(6900):823. 14. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, Naber SP, Weinberg RA: The melanocyte differentiation program predisposes to metastasis after neoplastic transfor- mation. Nat Genet 2005, 37(10):1047-1054. 15. Abramova L, Slingluff CL Jr., Patterson JW: Problems in the inter- pretation of apparent "radial growth phase" malignant melanomas that metastasize. J Cutan Pathol 2002, 29(7):407-414. 16. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pul- liam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M: The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005, 102(17):6092-6097. 17. Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D, Schuchter L, Van Belle TJ, Albelda S, Tahin P, Herlyn M, Elder DE: Progression-related expression of beta3 integrin in melano- mas and nevi. Hum Pathol 1999, 30(5):562-567. 18. Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Mont- gomery AM, Cheresh DA, Brooks PC: Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulat- ing tumor cell survival. Cancer Res 1999, 59(11):2724-2730. 19. Sturm RA, Satyamoorthy K, Meier F, Gardiner BB, Smit DJ, Vaidya B, Herlyn M: Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res 2002, 62(1):226-232. 20. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR: KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996, 88(23):1731-1737. 21. Shirasaki F, Takata M, Hatta N, Takehara K: Loss of expression of the metastasis suppressor gene KiSS1 during melanoma Page 15 of 18 (page number not for citation purposes)